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Impact of Modifiable Bleeding Risk Factors on Major Bleeding in
Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
Paulus Kirchhof, MD; Sylvia Haas, MD; Pierre Amarenco, MD, PhD; Susanne Hess, MD; Marc Lambelet, Dipl-Math; Martin van Eickels, MD;
Alexander G. G. Turpie, MD; A. John Camm, MD; on behalf of the XANTUS Investigators*
Background-—Reducing major bleeding events is a challenge when managing anticoagulation in patients with atrial fibrillation. This
study evaluated the impact of modifiable and nonmodifiable bleeding risk factors in patients with atrial fibrillation receiving
rivaroxaban and estimated the impact of risk factor modification on major bleeding events.
Methods and Results-—Modifiable and nonmodifiable risk factors associated with major bleeding events were identified from the
XANTUS (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation) prospective registry data set (6784 rivaroxaban-
treated patients). Parameters showing univariate association with bleeding were used to construct a multivariable model identifying
independent risk factors. Modeling was used to estimate attributed weights to risk factors. Heavy alcohol use (hazard ratio [HR]
=2.37; 95% CI 1.24–4.53); uncontrolled hypertension (HR after parameter-wise shrinkage=1.79; 95% CI 1.05–3.05); and
concomitant treatment with antiplatelets, nonsteroidal anti-inflammatory drugs, or paracetamol (HR=1.80; 95% CI 1.24–2.61) were
identified as modifiable, independent bleeding risk factors. Increasing age (HR=1.25 [per 5-year increment]; 95% CI 1.12–1.38);
heart failure (HR=1.97; 95% CI 1.36–2.86); and vascular disease (HR=1.91; 95% CI 1.32–2.77) were identified as nonmodifiable
bleeding risk factors. Overall, 128 (1.9%) patients experienced major bleeding events; of these, 11% had no identified bleeding risk
factors, 50% had nonmodifiable bleeding risk factors only, and 39% had modifiable bleeding risk factors (with or without
nonmodifiable risk factors). The presence of 1 modifiable bleeding risk factor doubled the risk of major bleeding.
Conclusions-—Elimination of modifiable bleeding risk factors is a potentially effective strategy to reduce bleeding risk in atrial
fibrillation patients receiving rivaroxaban.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01606995. ( J Am Heart Assoc. 2020;9:
e009530. DOI: 10.1161/JAHA.118.009530.)
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O ral anticoagulation with vitamin K antagonists or non-vitamin K antagonist oral anticoagulants (NOACs)1
prevents stroke and prolongs life in patients with atrial
fibrillation (AF).1–4 Although most patients benefit from oral
anticoagulation, all anticoagulants increase the risk of major
bleeding, including fatal events. Several bleeding risk factors
(eg, higher age or prior stroke)5–9 cannot be modified and also
identify patients with AF at high risk of stroke. Others, such as
concomitant therapy with antiplatelet agents or uncontrolled
hypertension, are modifiable and offer opportunities to reduce
bleeding risk.3 Although recent guidelines on the management
of AF recommend treating modifiable bleeding risk factors,3
the impact of such factors on outcomes in anticoagulated
patients with AF has never been quantified. Furthermore,
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bleeding risk factors in patients treated with NOACs may be
different from bleeding risk factors in patients treated with
vitamin K antagonists. In this analysis, modifiable and
nonmodifiable risk factors of major bleeding were identified
in an unselected cohort of AF patients treated with the NOAC
rivaroxaban, and the potential maximum benefits of reducing
modifiable risk factors were modeled.
Methods
The authors declare that all supporting data are available
within the article and its online supplementary files.
Patients and Outcome Definitions
The XANTUS (Xarelto for Prevention of Stroke in Patients With
Atrial Fibrillation) data set was analyzed; XANTUS, a safety
study mandated by the European Medicines Agency, was a
real-world, prospective, observational registry that enrolled
unselected adult patients (aged ≥18 years) with AF who had
been newly prescribed rivaroxaban for stroke/systemic
embolism prevention in routine clinical practice.10 Patients
who did not provide informed consent were ineligible and
contraindications were considered according to the product
label. Dose and duration of rivaroxaban therapy were solely at
the discretion of the prescribing physician. The study received
all appropriate approval by Health Authorities, independent
Ethics Committees, and Independent Review Boards. All
participants gave written informed consent to participate in
the study.10 All bleeding events reported by the investigators
were analyzed and adjudicated centrally as major or nonmajor
based on predefined criteria in accordance with the Interna-
tional Society on Thrombosis and Haemostasis definition of
major bleeding. An event was considered treatment emergent if
it started on or after the day of the first dose of rivaroxaban and
up to 2 days after the last dose. Only treatment-emergent
major bleeding events were used in the analysis because
nonmajor bleeding eventsmay be less accurately recorded in an
observational setting, and are less likely to be as clinically
relevant; bleeding events occurring after discontinuation of
rivaroxaban are unlikely to be treatment related. Patient
characteristics, including comorbidities and potential risk
factors for bleeding events, were recorded as assessed by the
treating physician at the initial screening visit before enrollment
in the study, except for creatinine clearance (CrCl) and weight
(used for body mass index calculation), which were first
available values, recorded at any time during the study.
Definitions for hypertension, heart failure, and vascular disease
are summarized in Table S1. Concomitant medications taken at
the time of commencing rivaroxaban therapy and initiated any
time after the start of rivaroxaban therapy were recorded during
the initial and follow-up visits, respectively. After the initial
screening visit, patients were followedup at3-month intervals
for up to 1 year or until 30 days after permanent discontinu-
ation (if <1 year) of rivaroxaban treatment.
Statistical Methods
All analyses were based on the safety analysis set, which
included all patients exposed to at least 1 dose of rivaroxaban
during the observation period. Potential risk factors were
explored using separate univariate Cox proportional hazard
models, which included all patients with available data for
each risk factor assessed. The univariate analyses included
both continuous and categorical versions of a variable where
applicable. Risk factors with a univariate P<0.10 were
considered as candidates. In case of high correlation among
factors (assessed using Kendall’s tau), candidates were
removed based on medical judgment. Additional risk factors
with P≥0.10 were chosen as candidates for the multivariable
model selection procedure for medical reasons. Medical
judgment was also used to decide whether continuously
measured variables were included as continuous (ie, age) or
categorical variables (ie, first available CrCl <50 mL/min
versus ≥50 mL/min; first available weight >60 kg versus
≤60 kg) in the multivariable model. The risk factors selected
Clinical Perspective
What Is New?
• In patients with atrial fibrillation treated with rivaroxaban,
heavy alcohol use, uncontrolled hypertension, and concomi-
tant treatment with antiplatelets, nonsteroidal anti-inflam-
matory drugs, or paracetamol were identified as modifiable,
independent bleeding risk factors; increasing age, heart
failure, and vascular disease were identified as nonmodifi-
able bleeding risk factors.
• Thirty-nine percent of patients who experienced major
bleeding events had at least 1 modifiable bleeding risk
factor (most of whom also had additional nonmodifiable risk
factors).
• The presence of 1 or more of the 3 independent modifiable
bleeding risk factors identified in this analysis was associ-
ated with a 2-fold increase in the risk of major bleeding.
What Are the Clinical Implications?
• Eliminating or reducing modifiable bleeding risk factors (eg,
heavy alcohol use, uncontrolled hypertension, and concomi-
tant therapy with antiplatelets, nonsteroidal anti-inflamma-
tory drugs, or paracetamol) in the context of integrated
atrial fibrillation care may be an effective strategy to reduce
the risk of bleeding in anticoagulated patients with atrial
fibrillation.
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after the univariate analyses (Table S2) were included into a
multivariable Cox regression model. A backward elimination
with a significance level of P=0.10 for keeping variables in the
model was performed to identify a model with multiple risk
factors. Patients with missing values were not included (ie, a
multiple imputation model was not performed). The propor-
tional hazards assumption of the Cox model and linearity of
age were assessed graphically (Figures S1 and S2). A
sensitivity analysis was carried out in which missing values
for CrCl were imputed. The model fit of the final multivariable
model was assessed visually using a calibration plot
(Figure S3),11 and model discrimination was assessed using
Harrell’s C statistic (Table S3).11 An internal validation of the
model was performed (ie, the C-statistic corrected for
optimism was calculated via the bootstrap technique [200
samples])11; parameter estimates were adjusted with param-
eter-wise shrinkage factors, and corresponding hazard ratios
(HRs) were determined.12
The identified risk factors in the final multivariable model
were divided into modifiable and nonmodifiable, and the
impact of the modifiable risk factors was assessed by
comparing the model-predicted probabilities of major bleed-
ing over time for selected types of patients by showing
modeled Kaplan–Meier curves for patients with or without
modifiable risk factors and by computing partial population-
attributable risks. The partial population-attributable risks give
the maximum proportion of events that could theoretically be
prevented if a specific risk factor (and any associated
pathologies) were completely eliminated/reversed. It is
applicable in cases where there is more than 1 risk factor
of interest and when the set of risk factors includes both
modifiable and nonmodifiable risk factors.13
Paulus Kirchhof and the co-authors had access to all the
data in the study. Paulus Kirchhof takes responsibility for its
integrity and data analysis. The study sponsor oversaw data
management and statistical analyses to adhere to Good
Clinical Practice standards, while the lead statistician oversaw
programming and validation of the statistical analyses.
Results
Treatment-emergent major bleeding events occurred in 128
patients over a mean treatment duration of 329 days (2.1
events per 100 patient-years). Compared with patients
without major bleeding events, those with major bleeding
events were older; more of them had heart failure and
vascular heart disease; and they were more often treated with
concomitant antiplatelets, nonsteroidal anti-inflammatory
drugs (NSAIDs), or paracetamol (Table 1). Overall, 118
patients (1.9 events per 100 patient-years) died and, of
these, 12 (0.2 per 100 patient-years) died of a bleeding event
(Table 2). Baseline characteristics of patients who had major
bleeding events or died, compared with patients not experi-
encing these outcomes, are included in Table S4. The mean
treatment duration (follow-up) ( SD) was 329 (115) days,
with a median treatment duration (interquartile range) of 366
(343–379) days. In total, 4223/6784 (62.2%) patients were
treated for 1 year.
The multivariable analysis included 4127 patients with all
data for candidate risk factors available (Figure 1). Compared
with patients excluded from the model, patients who were
included had a similar mean age and a similar proportion of
them were elderly (aged ≥75 years old); however, they were
more likely to have heart failure or vascular disease and, as
expected based on rivaroxaban dosing recommendations
being dependent on renal function, a higher proportion
received an initial daily dose of 15 mg (Table S5). Differences
in baseline characteristics between the 105 patients with
major bleeding and the 4022 patients without major bleeding,
who were included in the model population, were similar to
the differences between patients with and without major
bleeding in the overall XANTUS population (Table S6). The
results of the multivariate analysis, which included all factors
that showed a tendency to be different in the univariate
comparison and those included in the model that were based
on medical judgment (Table S2), identified 6 independent
factors associated with major bleeding on treatment with
rivaroxaban (Figure 2):
1. Concomitant antiplatelet, NSAID, or paracetamol treat-
ment at any time during the study (HR=1.80; 95% CI 1.24–
2.61).
2. Uncontrolled hypertension, defined as blood pressure
>160/90 mm Hg at baseline (HR=1.79; 95% CI 1.05–
3.05).
3. Heavy (>80 g alcohol/d: HR=2.37; 95% CI 1.24–4.53;
P=0.009) but not moderate (40–80 g alcohol/d: HR=0.96;
95% CI 0.62–1.46; P=0.819) alcohol use at baseline.
4. Increasing age at baseline (HR after parameter-wise
shrinkage=1.25 [per 5-year increase]; 95% CI 1.12–1.38).
5. Heart failure at baseline (HR=1.97; 95% CI 1.36–2.86).
6. Vascular disease at baseline (HR=1.91; 95% CI 1.32–2.77).
These risk factors were confirmed in a sensitivity analysis
using major bleeding or death as outcome parameters
(Table S7), with the exception of heavy alcohol use (defined
in Table S8) and uncontrolled hypertension (defined in
Table S1). In the univariate analyses, HRs for concomitant
antiplatelets, NSAIDs, and paracetamol were 1.69 (95% CI
1.13–2.55; P=0.012), 1.73 (95% CI 0.76–3.92; P=0.191), and
2.64 (95% CI 1.34–5.19; P=0.005), respectively (Table S9). An
additional sensitivity analysis, which included 87% of the
overall XANTUS population by imputing missing CrCl values,
showed consistent outcomes in the multivariable model
(Table S10).
DOI: 10.1161/JAHA.118.009530 Journal of the American Heart Association 3
Predictors of Major Bleeding in XANTUS Kirchhof et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on February 24, 2020
In total, 1634 patients (24%) had at least 1 modifiable
bleeding risk factor: 541 had modifiable risk factors only and
1093 patients had both modifiable and nonmodifiable risk
factors. Incidence rates of major bleeding (events per 100
patient-years [95% CI]) increased with the number of modi-
fiable risk factors (0, 1, or 2 risk factors, respectively) from
1.66 (1.31–2.07, no risk factor) to 3.56 (2.62–4.72, 1 risk
factor) and 4.16 (0.50–15.02, 2 risk factors) (Table 3).
Table 1. Baseline Demographics and Clinical Characteristics of Patients With and Without Treatment-Emergent Major Bleeding
Events in XANTUS
All Patients (N=6784)
Patients With Major
Bleeding (n=128)
Patients Without Major
Bleeding (n=6656) P Value
Age, y, meanSD 71.59.95 75.99.35 71.49.94 <0.001
<75 y, n (%) 3975 (58.6) 52 (40.6) 3923 (58.9) <0.001
≥75 y, n (%) 2809 (41.4) 76 (59.4) 2733 (41.1) <0.001
Male, n (%) 4016 (59.2) 81 (63.3) 3935 (59.1) 0.3457
Body mass index, kg/m2, meanSD 28.34.98 28.15.25 28.34.98 0.5769
First available creatinine clearance, n (%)    0.0246
<80 mL/min 2961 (43.6) 87 (68.0) 2874 (43.2) 
≥80 mL/min 1491 (22.0) 27 (21.1) 1464 (22.0) 
Missing 2332 (34.4) 14 (10.9) 2318 (34.8) 
Hepatic insufficiency, n (%)* 137 (2.0) 6 (4.7) 131 (2.0) 0.0303
Rivaroxaban dose (first documented), n (%)    0.0004
15 mg 1410 (20.8) 39 (30.5) 1371 (20.6) 
20 mg 5336 (78.7) 86 (67.2) 5250 (78.9) 
Other/missing 38 (0.6) 3 (2.3) 35 (0.5) 
Concomitant ASA or NSAID, n (%) 1118 (16.5) 33 (25.8) 1085 (16.3) 0.0042
Concomitant dual antiplatelets, n (%) 105 (1.5) 5 (3.9) 100 (1.5) 0.0291
Concomitant antiplatelet, NSAID, or paracetamol, n (%) 1363 (20.1) 41 (32.0) 1322 (19.9) 0.0007
Concomitant CYP3A4 or P-gp inhibitors, n (%)† 1313 (19.4) 40 (31.3) 1273 (19.1) 0.0006
Concomitant paracetamol, n (%) 191 (2.8) 9 (7.0) 182 (2.7) 0.0036
Active cancer, n (%) 105 (1.5) 3 (2.3) 102 (1.5) 0.4614
Prior bleeding, n (%) 49 (0.7) 1 (0.8) 48 (0.7) 0.9366
Ulcerative gastrointestinal disease, n (%) 27 (0.4) 1 (0.8) 26 (0.4) 0.4869
Uncontrolled hypertension, n (%) 275 (4.1) 8 (6.3) 267 (4.0) 0.2034
Prior stroke, n (%) 935 (13.8) 22 (17.2) 913 (13.7) 0.2598
Prior MI, n (%) 688 (10.1) 19 (14.8) 669 (10.1) 0.0752
Heart failure at baseline, n (%) 1265 (18.6) 45 (35.2) 1220 (18.3) <0.0001
Platelet count <80 000, n (%) 39 (0.6) 2 (1.6) 37 (0.6) 0.3577
Diabetes mellitus, n (%) 1333 (19.6) 31 (24.2) 1302 (19.6) 0.1890
Vascular disease, n (%) 1685 (24.8) 55 (43.0) 1630 (24.5) <0.0001
Heavy alcohol use, n (%) 54 (0.8) 3 (2.3) 51 (0.8) 0.0791
Anemia/reduced hemoglobin, n (%) 203 (3.0) 6 (4.7) 197 (3.0) 0.2558
Known coagulopathy, n (%) 19 (0.3) 1 (0.8) 18 (0.3) 0.2787
Bridging therapy during interruptions, n (%) 100 (1.5) 11 (8.6) 89 (1.3) <0.0001
The baseline demographics and clinical characteristics from patients in the XANTUS (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation) study were stratified according to
the presence or absence of major bleeding. ASA indicates acetylsalicylic acid; CYP3A4, cytochrome P450 3A4; MI, myocardial infarction; NSAID, nonsteroidal anti-inflammatory drug; P-gp,
P-glycoprotein.
*Defined as “abnormal liver function” by the study investigator.
†Strong, moderate, and weak inhibitors were included.
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Incidences of major bleeding or death also increased with the
number of modifiable risk factors (Table S11). Importantly,
50/128 (39%) patients who had a bleeding event had at least
1 modifiable bleeding risk factor (most of whom also had
additional nonmodifiable risk factors) (Figure 3), suggesting
that a substantial proportion of bleeding events could be
attributable to modifiable bleeding risk factors. An additional
analysis testing for interactions between the modifiable risk
Table 2. Characteristics of Patients Who Died of a Bleeding Event in XANTUS
Patient Event Concomitant Cardiovascular Conditions
1: 73 y old ICH, 7 mo after rivaroxaban start (15 mg od) Hypertension
2: 85 y old ICH, 14 d after rivaroxaban start (15 mg od) Prior TIA, CHF, vascular disease, hypertension
3: 74 y old ICH, 6 mo after rivaroxaban start (15 mg od) Vascular disease, diabetes mellitus, hypertension
4: 80 y old ICH, 4 mo after rivaroxaban start (20 mg od) CHF
5: 60 y old ICH, 9 mo after rivaroxaban start (20 mg od) Obesity, CHF, hypertension
6: 63 y old ICH, 8 mo after rivaroxaban start (20 mg od) Hypertension
7: 66 y old ICH, 10 mo after rivaroxaban start (20 mg od) CHF, vascular disease, hypertension
8: 70 y old Extracranial bleeding, 3 mo after rivaroxaban start (20 mg od) CHF, hypertension
9: 76 y old GI bleeding, 11 mo after rivaroxaban start (20 mg od) Anemia and prior hemorrhoidal bleeding, CHF, vascular disease,
diabetes mellitus, obesity
10: 56 y old Rectal bleeding, 4 mo after rivaroxaban start (20 mg od) Prior systemic embolism, CHF, hypertension, obesity
11: 74 y old Intra-alveolar hemorrhage, 6 wks after rivaroxaban start (15 mg od) Hypertension
12: 87 y old Aortic aneurysm rupture, 10 mo after rivaroxaban start (15 mg od) CHF, vascular disease, hypertension
All patients had atrial fibrillation and were treated with rivaroxaban. CHF indicates congestive heart failure; GI, gastrointestinal; ICH, intracranial hemorrhage; od, once daily; TIA, transient
ischemic attack; XANTUS, Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation.
Figure 1. Flow chart of patients in this analysis (STROBE format). *Patients can have missing data in
more than 1 candidate risk factor. †Patients who died (treatment-emergent) with bleeding as cause of death
based on model population. ‡Patients who died (treatment-emergent) excluding bleeding as cause of death
based on model population. CrCl indicates creatinine clearance.
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factors and age (as a continuous risk factor) showed no
significant interaction. P values for interactions between age
and alcohol consumption; concomitant antiplatelet, NSAIDs,
or paracetamol use; and uncontrolled hypertension were
0.746, 0.997, and 0.171, respectively (Table S12).
Patients without modifiable bleeding risk factors had a
bleeding risk of 1.7% at day 360, increasing to 3.3% in patients
with at least 1 modifiable bleeding risk factor (Figure 4A). The
discrimination power of modifiable bleeding risk factors was
similar to the discriminatory power of the published HAS-BLED
and ORBIT bleeding risk scores (Table S13): major bleeding
incidence rates (events per 100 patient-years [95% CI]) for
patients with low, medium, and high HAS-BLED bleeding risk
(score=0, 1–2, and ≥3, respectively) were 0.36 (0.01–2.03),
1.89 (1.49–2.35), and 2.88 (2.12–3.82), respectively. Bleeding
rates for low, medium, and high ORBIT score (0–2, 3, and 4–7,
respectively) were 2.61 (1.72–3.80), 5.89 (3.13–10.07), and
5.54 (2.76–9.91), respectively.
The increased bleeding risk was confirmed in a modeling
analysis estimating the impact of modifiable bleeding risk
factors in patients with an average profile of nonmodifiable
risk factors. The probability of major bleeding events rose
from 2% at day 360 in patients without modifiable bleeding
risk factors to 16% in patients with all 3 modifiable risk factors
(Figure 4B). The partial population-attributable risk analysis
showed that eliminating all modifiable bleeding risk factors
would reduce the bleeding risk by up to 16%; values
attributable to bleeding risk for each modifiable risk factor
can be found in Table 4.
Discussion
Main Findings
This analysis quantified the impact of modifiable and
nonmodifiable bleeding risk factors in an unselected cohort
Figure 2. Risk factors associated with major bleeding events in XANTUS (Xarelto for Prevention of Stroke
in Patients With Atrial Fibrillation). Forest plot showing all factors associated with major bleeding events in
the XANTUS population after parameter-wise shrinkage. Alcohol consumption was defined as: abstinent
(0 g alcohol/d); mild (<40 g alcohol/d); moderate (40–80 g alcohol/d); or heavy (>80 g alcohol/d). AP
indicates antiplatelet; NSAID, nonsteroidal anti-inflammatory drug.
Table 3. Major Bleeding in the XANTUS Population Stratified by Number of Modifiable Bleeding Risk Factors
Number of Modifiable
Risk Factors Overall, n (%)
Patients With Major
Bleeding*, n (%)
Incidence Proportion,
% (95% CI)
Incidence Rate Events
Per 100 Years (95% CI)
0 5150 (75.9) 78 (1.5) 1.51 (1.20–1.89) 1.66 (1.31–2.07)
1 1577 (23.2) 48 (3.0) 3.04 (2.25–4.02) 3.56 (2.62–4.72)
≥2† 57 (0.8) 2 (3.5) 3.51 (0.43–12.11) 4.15 (0.50–14.98)
Number of patients and major bleeding events from the XANTUS (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation) study were stratified according to number of modifiable
risk factors.
*Treatment emergent adjudicated.
†Only 1 patient had 3 modifiable bleeding risk factors and did not experience a bleeding event.
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of patients with AF treated with rivaroxaban in routine clinical
practice. Iterative analyses identified 3 modifiable and 3
nonmodifiable risk factors associated with bleeding in
patients with AF receiving rivaroxaban. Almost 40% of major
bleeding events occurred in patients with at least 1 modifiable
risk factor. Elimination of modifiable bleeding risk factors (eg,
heavy alcohol use, uncontrolled hypertension, and concomi-
tant therapy with antiplatelet agents, NSAIDs, or paracetamol)
and in the context of integrated AF care14,15 thus emerges as
a potentially effective intervention to reduce bleeding risk in
anticoagulated patients with AF.
Modifiable Bleeding Risk Factors in
Anticoagulated Patients With AF
The presence of 1 or more of the 3 independent modifiable
bleeding risk factors identified in this analysis approximately
doubled the risk of major bleeding (Figure 4A); the modeling
analysis showed additive effects with an increasing number of
risk factors (Figure 4B). Thirty-nine percent of major bleeding
events occurred in patients with at least 1modifiable risk factor,
suggesting that it may have been possible to reduce the risk of
bleeding in a large proportion of the study population. An
additional benefit of a reduced risk of bleeding is a potentially
improved treatment adherence and persistence, which could
lead to preventing thromboembolic events more effectively.
Furthermore, reducing life-threatening bleeding events may be
an important factor in reducing the risk of overall mortality in
patients with AF receiving NOACs.
Concomitant therapy with antiplatelet drugs or NSAIDs
increased bleeding risk in our study, confirming observations
made by others.6,8 NSAIDs reduce gastric protection and
inhibit cyclooxygenase in platelets.16 The mechanism of
action of paracetamol is less clear, but it is thought to
involve the inhibition of cyclooxygenase and may also reduce
gastric protection, although it is generally considered to be a
safer alternative to NSAIDs in patients at an increased risk of
bleeding.17 In XANTUS, there was no difference in bleeding
risk in patients on paracetamol compared with those on
NSAIDs. The increased risk of bleeding associated with
paracetamol use may be surprising, but it is consistent with
another recent analysis.18 It was not possible to determine
conclusively whether this resulted directly from the use of
paracetamol or another associated factor. Paracetamol use
did not correlate with any other risk factors included in the
analysis, but it is possible that the association could have
resulted from the preferential prescription of paracetamol to
patients who were already at an increased risk of bleeding.17
Overall, these results underpin the need to avoid antiplatelet
or NSAID exposure in anticoagulated patients with AF,3 which
are still commonly coprescribed.19
Additional analyses demonstrated that there were no differ-
ences in bleeding risk when antiplatelet agents, NSAIDs, and
paracetamol were analyzed separately (Table S9), suggesting
that the bleeding risk in patients receiving antiplatelet agents,
which are usually taken chronically, and paracetamol/NSAIDs,
which are normally taken on an as-needed, short-term basis, are
similar. One possible explanation for this is that chronic pain
management in elderly patients with AF (eg, due to arthritis or
arthrosis) can result in regular use of paracetamol/NSAIDs. It
should be noted that cessation of antiplatelet therapy to reduce
the risk of bleeding may not be clinically indicated in all patients
12
(9%)
541 (8%)
3055 (45%)
2095
(31%) 1093
(16%)14
(11%)
38
(30%)
64
(50%)
Modifiable risk factorsPatients
with major
bleeding
Study population
Modifiable and nonmodifiable risk factors
Nonmodifiable risk factors
No risk factors
Figure 3. Patient risk profiles. Donut chart showing study population (outer ring) and patients who
experienced a major bleeding event (inner ring) according to the presence of bleeding risk factors, split into
modifiable and nonmodifiable risk factors. Age ≥75 years was used as a cut-off point for age to qualify as a
nonmodifiable risk factor.
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with AF, such as those with a recent acute coronary syndrome or
recent elective percutaneous coronary intervention, for whom
guidelines suggest concomitant antiplatelet and anticoagulation
therapy for a limited 6- to 12-month time period.3
Uncontrolled hypertension is an independent risk factor for
intracranial hemorrhage in anticoagulated5–7 and nonantico-
agulated20–22 patients, consistent with our analysis. Elevated
pulse pressure and intravascular pressure driving chronic
A
B
Figure 4. Analysis of bleeding risk in patients with 0 or ≥1 modifiable bleeding risk factors. A, Kaplan–
Meier curve of bleeding events in patients with 0 or ≥1 modifiable risk factors for bleeding. Patients with
≥1 modifiable risk factor (heavy alcohol use, uncontrolled hypertension, and concomitant therapy with
antiplatelet agents, NSAIDs, or paracetamol) were twice as likely to experience a bleeding event
compared with patients without modifiable risk factors. B, Model-predicted probabilities of bleeding
events in patients with an average profile with respect to all risk factors (yellow), average with respect to
all nonmodifiable risk factors and no (purple), 1 (green), 2 (red), or all 3 (blue) modifiable risk factors.
Predicted probabilities shown at the end of each projection are for day 360. NSAID indicates
nonsteroidal anti-inflammatory drug.
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arterial vessel damage and precipitating acute rupture of
vulnerable vessels are potential explanations for this associ-
ation. In view of the additional benefits of controlling
hypertension for stroke prevention,20 optimal control of blood
pressure should be a priority in anticoagulated patients with
AF at risk of stroke.
The link between heavy alcohol consumption and bleeding
is less well understood. Gastritis, esophagitis or liver
dysfunction, and alcohol-induced inhibition of platelets23,24
could be responsible for this effect, in addition to the
potentially increased chance of overdosing.
Comparison to Published Bleeding Risk Scores
Concomitant antiplatelet therapy is a component of the HAS-
BLED and ORBIT scores; heavy alcohol use is included in HAS-
BLED and HEMORR2HAGES; and hypertension or uncontrolled
hypertension are included in the ATRIA, HAS-BLED, and
HEMORR2HAGES scores. These scores were developed and
validated in patients treated with vitamin K antagonists or in
randomized trials evaluating NOAC therapy (AMADEUS
[Evaluating the Use of SR34006 Compared to Warfarin or
Acenocoumarol in Patients With Atrial Fibrillation], ARISTOTLE
[Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation], and RE-LY [Randomized Evaluation
of Long Term Anticoagulant Therapy]).5–9 In addition, the HAS-
BLED, ATRIA, and ORBIT scores have been compared using
registry data on patients receiving NOACs and were found to
have modest predictive value.25 Our analysis confirmed these
bleeding risk factors in an unselected cohort of patients
treated with rivaroxaban in routine clinical practice, and the
predictive discrimination of independent risk factors in our
analysis was compared with ORBIT and HAS-BLED scores using
Harrell’s C analysis. As well as the 3 modifiable bleeding risk
factors, 3 additional, nonmodifiable bleeding risk factors were
identified (age, vascular disease, and heart failure).3 Age is a
component of the ATRIA, HAS-BLED, HEMORR2HAGES, and
ORBIT bleeding risk scores. Vascular disease is not included in
these scores and emerges as a novel bleeding risk factor in this
analysis. The finding that heart failure is a risk factor for major
bleeding in the XANTUS population is in accordance with
another large retrospective study of unselected patients with
AF treated with rivaroxaban in routine clinical practice.26 All 3
are recognized stroke risk factors and part of the CHA2DS2-
VASc score. Although potentially useful to identify patients
who are at high risk of stroke and bleeding, these factors will
not inform the decision for anticoagulation.3,4,19
Major bleeding events were found in 2% of patients per
year of treatment in this analysis, which is within the range of
the rates of major bleeding observed in the phase III NOAC
trials.27–30 The bleeding rate appears acceptable compared
with the stroke risk in similar patients without anticoagula-
tion,3,31 but this also underpins the need to reduce bleeding
risk further in patients with AF receiving NOAC therapy.
Several additional risk factors for bleeding in anticoagu-
lated patients with AF have been proposed,5–9 such as
anemia, chronic kidney disease, impaired liver function,
history of major bleeding, or previous stroke. No association
between these risk factors and major bleeding was found in
XANTUS, suggesting these are less relevant in patients
treated with rivaroxaban.
Limitations
Enrollment into XANTUS was based on voluntary participation
by centers and patients, which may have created patient or
physician selection bias. Predefined criteria for events and
central adjudication are means to ensure internal validity of the
results, but replication in independent cohorts is warranted.
Several biomarkers are associated with bleeding events in
patients on anticoagulation treatment,7,9 but biomarkers were
not recorded in XANTUS and, therefore, their effect on bleeding
cannot be measured. Patient risk factors for bleeding events,
except for CrCl, weight, and concomitant medications, were
based on patient characteristics recorded at the screening visit
before enrollment into the study; potential changes in patient
risk factors (eg, development of hypertension or changes in
alcohol consumption) over the duration of the study were not
Table 4. Attributable Bleeding Risk for Modifiable Risk
Factors in XANTUS
Risk Factors Partial PAR (95% CI)
Uncontrolled hypertension 0.025 (0.019 to 0.069)
Heavy alcohol use 0.017 (0.008 to 0.042)
Concomitant antiplatelets, NSAIDs, or
paracetamol use
0.126 (0.008 to 0.242)
Uncontrolled hypertension and heavy
alcohol use
0.042 (0.020 to 0.104)
Uncontrolled hypertension and
concomitant antiplatelets, NSAIDs, or
paracetamol use
0.149 (0.004 to 0.289)
Heavy alcohol use and concomitant
antiplatelets, NSAIDs, or paracetamol
use
0.140 (0.014 to 0.262)
Uncontrolled hypertension and heavy
alcohol use and concomitant
antiplatelets, NSAIDs, or paracetamol
use
0.163 (0.009 to 0.310)
The PAR describes the maximum proportion of major bleeding events that could
theoretically be prevented if a specific risk factor and any associated pathologies were to
be completely eliminated/reversed from a target population. The partial PAR is of
interest where there is more than 1 risk factor of interest and when the set of risk
factors includes modifiable and nonmodifiable risk factors. NSAID indicates nonsteroidal
anti-inflammatory drug; PAR, population-attributable risk; XANTUS, Xarelto for Prevention
of Stroke in Patients With Atrial Fibrillation.
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considered. Additionally, patient-reported measures were used
to estimate alcohol consumption; it is possible that some
patients did not estimate their consumption accurately. Some
heavy drinkers may have been included in the missing data
group and therefore excluded from the analysis. Moreover,
because of the noninterventional study design, a large
proportion (39%) of patients had missing data and were
excluded from the multivariate model selection procedure,
which may limit the validity of the data set; however, an
additional sensitivity analysis, imputing missing CrCl values
(the most frequent source of missing data), showed consistent
outcomes in the multivariable model. Additionally, because this
analysis aimed to identify a simple model of risk factors,
potential interactions between risk factors were not considered
in the model selection. Nonetheless, interactions between age
and modifiable risk factors, which were assessed by adding
these variables individually to the final model, were not
significant. The study only included patients receiving rivarox-
aban and it is therefore unclear whether the findings also apply
to other NOACs. Lastly, the potential impact of modifying
bleeding risk factors to reduce bleeding risk assumes complete
elimination and reversal of any pathological changes associ-
ated with said risk factor (eg, liver disease caused by heavy
alcohol consumption or peptic ulcers causally associated with
use of antiplatelet agents/NSAIDs); therefore, this represents
a maximal theoretical benefit and would ideally be confirmed in
a controlled trial comparing interventions to reduce modifiable
bleeding risk factors with usual care. Without such data, it
seems prudent to control blood pressure, to avoid heavy
alcohol consumption, and reduce exposure to antiplatelets,
NSAIDs, and paracetamol (unless clinically indicated) to
minimize bleeding events in patients with AF anticoagulated
with rivaroxaban.
Conclusions
This analysis identified 3 modifiable factors that increase
bleeding risk in patients receiving NOAC therapy with rivarox-
aban; elimination or reduction of these risk factors may reduce
major bleeding events in anticoagulated patients with AF.
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 Table S1. Definitions of uncontrolled hypertension, vascular disease, and heart 
failure. 
Parameter Definition used 
Uncontrolled 
hypertension 
Blood pressure >160/90 mm Hg 
Vascular disease Recorded according to type (peripheral artery disease, ischemic 
heart disease, or cerebrovascular disease), as assessed by the 
treating physician 
Heart failure Clinically defined using reduced left ventricular ejection fraction 
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 Table S2. Risk factors selected after univariate analysis for inclusion in the 
multivariable Cox regression model. 
 HR (95% CI) P-value 
Risk factors included in multivariate model based on P<0.1 in univariate analysis 
Age at baseline (5-year increase) 1.31 (1.18–1.45) <0.001 
Heart failure at baseline: Yes vs No 2.42 (1.68–3.47) <0.001 
Vascular disease at baseline: Yes vs No 2.31 (1.63–3.28) <0.001 
Concomitant antiplatelet therapy, NSAIDs, or paracetamol 
use at any time during study: Yes vs No 
1.97 (1.36–2.86) <0.001 
Rivaroxaban dose (first documented): Overall  <0.001 
20 mg vs 15 mg 0.57 (0.39–0.83) 0.003 
Other or missing vs 15 mg 3.16 (0.98–10.23) 0.055 
History of hypertension: Yes vs No 1.80 (1.12–2.91) 0.015 
Concomitant dual antiplatelet therapy at any time during 
study: Yes vs No 
2.99 (1.22–7.32) 0.016 
Hepatic insufficiency: Yes vs No 2.38 (1.05–5.40) 0.038 
Alcohol consumption at baseline: Overall  0.091 
Alcohol consumption at baseline: Heavy vs Abstinent or 
mild 
3.12 (0.99–9.82) 0.052 
Alcohol consumption at baseline: Medium vs Abstinent 
or mild 
0.71 (0.35–1.46) 0.355 
Risk factors included in multivariate model based on medical judgment 
Concomitant CYP3A4 or P-gp inhibitors* at any time 
during study (modelled as time dependent): Yes vs No 
1.41 (0.93–2.13) 0.105 
Renal insufficiency: First available CrCl <50 mL/min vs 
≥50 mL/min 
1.46 (0.92–2.33) 0.109 
Uncontrolled hypertension: Yes vs No 1.64 (0.80–3.36) 0.175 
Anemia or reduced hemoglobin#: Yes vs No 1.70 (0.75–3.85) 0.207 
Prior stroke: Yes vs No 1.27 (0.80–2.02) 0.301 
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 Sex: Male vs Female 1.18 (0.82–1.69) 0.368 
First available weight: >60 kg vs ≤60 kg 0.86 (0.46–1.61) 0.644 
Previous labile INR documented: Yes vs No 1.11 (0.68–1.81) 0.676 
*Strong, moderate and weak inhibitors were included. 
#Anemia as recorded at baseline; hemoglobin data based on first available data recorded at 
baseline or at any time during the study. 
CI indicates confidence interval; CrCl, creatinine clearance; CYP3A4, cytochrome P450 3A4; 
HR, hazard ratio; INR, international normalized ratio; NSAID, nonsteroidal anti-inflammatory 
drug; P-gp, P-glycoprotein. 
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 Table S3. Internal validation of XANTUS bleeding model using an optimism-corrected 
version of Harrell’s C-index. 
Apparent C* Averaged optimism 
Estimate O#  
Harrell’s C corrected for 
optimism estimation† 
0.728 0.036 0.692 
*Calculation of the apparent C using all patients with backward selection of the variables. 
#Average value from 200 bootstrap samples. 
†Corrected for optimism estimation.
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 Table S4. Baseline demographics and clinical characteristics of patients with and without treatment-emergent major bleeding events 
or treatment-emergent death events in XANTUS. 
 All patients 
(N=6784) 
Patients with 
major 
bleeding or 
death 
(n=232) 
Patients 
without major 
bleeding or 
death 
(n=6552) 
P-value 
Age years, mean ± SD 71.5±9.95 76.6±10.07 71.3±9.89 <0.001 
<75 years, n (%) 3975 (58.6) 90 (38.8) 3885 (59.3) <0.001 
≥75 years, n (%) 2809 (41.4) 142 (61.2) 2667 (40.7) <0.001 
Male, n (%) 4016 (59.2) 137 (59.1) 3879 (59.2) 0.9566 
Body mass index, kg/m2, mean ± SD 28.3±4.98 27.6±5.68 28.4±4.95 0.0425 
First available creatinine clearance, n (%)    
 
<80 mL/min 2961 (43.6) 145 (62.5) 2816 (43.0) 0.0049 
≥80 mL/min 1491 (22.0) 46 (19.8) 1445 (22.1) 0.0049 
Missing 2332 (34.4) 41 (17.7) 2291 (35.0) 0.0049 
Hepatic insufficiency, n (%)* 137 (2.0) 12 (5.2) 125 (1.9) 0.0005 
Rivaroxaban dose (first documented), n (%)    
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 15 mg 1410 (20.8) 82 (35.3) 1328 (20.3) <0.0001 
20 mg 5336 (78.7) 144 (62.1) 5192 (79.2) <0.0001 
Other/missing 38 (0.6) 6 (2.6) 32 (0.5) <0.0001 
Concomitant ASA or NSAIDs, n (%) 1118 (16.5) 51 (22.0) 1067 (16.3) 0.0215 
Concomitant dual antiplatelets, n (%) 105 (1.5) 8 (3.4) 97 (1.5) 0.0170 
Concomitant antiplatelet, NSAIDs, or 
paracetamol, n (%) 
1363 (20.1) 72 (31.0) 1291 (19.9) <0.0001 
Concomitant CYP3A4 or P-gp inhibitors, n (%)# 1313 (19.4) 59 (25.4) 1254 (19.1) 0.0171 
Concomitant paracetamol, n (%) 191 (2.8) 21 (9.1) 170 (2.6) <0.0001 
Active cancer, n (%) 105 (1.5) 9 (3.9) 96 (1.5) 0.0034 
Prior bleeding, n (%) 49 (0.7) 3 (1.3) 46 (0.7) 0.2961 
Ulcerative gastrointestinal disease, n (%) 27 (0.4) 2 (0.9) 25 (0.4) 0.2533 
Uncontrolled hypertension, n (%) 275 (4.1) 10 (4.3) 265 (4.0) 0.8401 
Prior stroke, n (%) 935 (13.8) 48 (20.7) 887 (13.5) 0.0019 
Prior MI, n (%) 688 (10.1) 41 (17.7) 647 (9.9) 0.0001 
Heart failure at baseline, n (%) 1265 (18.6) 92 (39.7) 1173 (17.9) <0.0001 
Platelet count <80 000, n (%) 39 (0.6) 2 (0.9) 37 (0.6) 0.9282 
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 Diabetes mellitus, n (%) 1333 (19.6) 60 (25.9) 1273 (19.4) 0.0154 
Vascular disease, n (%) 1685 (24.8) 91 (39.2) 1594 (24.3) <0.0001 
Heavy alcohol use, n (%) 54 (0.8) 5 (2.2) 49 (0.7) 0.0089 
Anemia/reduced hemoglobin, n (%) 203 (3.0) 19 (8.2) 184 (2.8) <0.0001 
Known coagulopathy, n (%) 19 (0.3) 2 (0.9) 17 (0.3) 0.0878 
Bridging therapy during interruptions, n (%) 100 (1.5) 12 (5.2) 88 (1.3) <0.0001 
The baseline demographics and clinical characteristics from patients from the XANTUS study were stratified according to the presence or 
absence of major bleeding or death. 
*Defined as ‘abnormal liver function’ by the study investigator. 
#Strong, moderate, and weak inhibitors were included. 
ASA indicates acetylsalicylic acid; CYP3A4, cytochrome P450 3A4; MI, myocardial infarction; NSAID, nonsteroidal anti-inflammatory drug; 
P-gp, P-glycoprotein; SD, standard deviation. 
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 Table S5. Baseline demographics and clinical characteristics of patients included in, and excluded from, the multivariable model 
selection procedure. 
 Patients included in 
multivariate model 
(n=4127) 
Patients excluded from 
multivariate model because 
of ≥1 missing value 
(n=2657) 
P-value 
Age years, mean ± SD 71.6±10.08 71.4±9.73 0.5007 
<75 years, n (%) 2402 (58.2) 1573 (59.2) 0.4144 
≥75 years, n (%) 1725 (41.8) 1084 (40.8)  
Male, n (%)* 2423 (58.7) 1593 (60.0) 0.2834 
BMI, kg/m2, mean ± SD 28.2±4.98 28.6±4.97 0.0273 
First available CrCl, n (%) – – 0.0098 
<50 mL/min 3518 (85.2) 294 (90.5)  
≥50 mL/min 
Missing 
609 (14.8) 
0 
31(9.5) 
2332 
 
Hepatic insufficiency, n (%)# 95 (2.3) 42 (1.6) 0.0393 
Rivaroxaban dose (first documented), n (%) – – <0.0001 
15 mg 931 (22.6) 479 (18.0)  
20 mg 3174 (76.9) 2162 (81.4)  
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 Other/missing 22 (0.5) 16 (0.6)  
Concomitant ASA or NSAIDs, n (%) 707 (17.1) 411 (15.5) 0.0716 
Concomitant dual antiplatelets, n (%) 66 (1.6) 39 (1.5) 0.6687 
Concomitant antiplatelet, NSAIDs, or paracetamol, n (%) 872 (21.1) 491 (18.5) 0.0078 
Concomitant CYP3A4 or P-gp inhibitors, n (%)† 855 (20.7) 458 (17.2) 0.0004 
Concomitant paracetamol, n (%) 150 (3.6) 41 (1.5) <0.0001 
Active cancer, n (%) 72 (1.7) 33 (1.2) 0.1016 
Prior bleeding, n (%) 31 (0.8) 18 (0.7) 0.7264 
Ulcerative gastrointestinal disease, n (%) 18 (0.4) 9 (0.3) 0.5339 
Uncontrolled hypertension, n (%) 149 (3.6) 126 (4.7) 0.0210 
Prior stroke, n (%)‡ 608 (14.7) 327 (12.3) 0.0049 
Prior MI, n (%) 440 (10.7) 248 (9.3) 0.0770 
Heart failure at baseline, n (%) 851 (20.6) 414 (15.6) <0.0001 
Platelet count, n (%) 
<80 000 
≥80,000 
Missing 
– 
23 (0.9) 
2529 (99.1) 
1575 
– 
16 (4.8) 
315 (95.2) 
2326 
<0.0001 
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 Diabetes mellitus, n (%) 856 (20.7) 477 (18.0) 0.0048 
Vascular disease, n (%) 1097 (26.6) 588 (22.1) <0.0001 
Alcohol consumption, n (%) 
Abstinent or mild 
Medium 
Heavy  
Missing 
– 
3724 (90.2) 
372 (9.0) 
31 (0.8) 
0 
– 
2209 (89.6) 
234 (9.5) 
23 (0.9) 
191 
0.5844 
Anemia/reduced hemoglobin, n (%) 162 (3.9) 41 (1.5) <0.0001 
Known coagulopathy, n (%) 9 (0.2) 10 (0.4) 0.2285 
Bridging therapy during interruptions, n (%) 80 (1.9) 20 (0.8) <0.0001 
% and P-values are based on number of patients with available data for each characteristic. 
*Information missing for 3 patients excluded from the multivariate model. 
#Defined as ‘abnormal liver function’ by the study investigator. 
†Strong, moderate and weak inhibitors were included. 
‡Information missing for 2 patients excluded from the multivariate model. 
ASA indicates acetylsalicylic acid; BMI, body mass index; CrCl, creatinine clearance; CYP3A4, cytochrome P450 3A4; MI, myocardial 
infarction; NSAID, nonsteroidal anti-inflammatory drug; P-gp, P-glycoprotein; SD, standard deviation. 
D
ow
nloaded from
 http://ahajournals.org by on February 24, 2020
 Table S6. Baseline demographics and clinical characteristics of patients with and without treatment emergent major bleeding in the 
model population (n=4127). 
 Patients with major 
bleeding 
(n=105) 
Patients without major 
bleeding 
(n=4022) 
P-value 
Age years, mean ± SD 75.9±9.5 71.5±10.1 <0.0001 
<75 years, n (%) 42 (40.0) 2360 (58.7) 0.0001 
≥75 years, n (%) 63 (60.0) 1662 (41.3)  
Male, n (%) 64 (61.0) 2359 (58.7) 0.6365 
BMI, kg/m2, mean ± SD 28.33±5.41 28.23±4.97 0.8544 
First available CrCl, n (%)   0.0698 
<50 mL/min 22 (21.0) 587 (14.6)  
≥50 mL/min 83 (79.0) 3435 (85.4)  
Hepatic insufficiency, n (%)* 6 (5.7) 89 (2.2) 0.0182 
Rivaroxaban dose (first documented), n (%)   0.0033 
15 mg 35 (33.3) 896 (22.3)  
20 mg 68 (64.8) 3106 (77.2)  
Other/missing 2 (1.9) 20 (0.5)  
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 Concomitant ASA or NSAIDs, n (%) 31 (29.5) 676 (16.8) 0.0006 
Concomitant dual antiplatelets, n (%) 5 (4.8) 61 (1.5) 0.0089 
Concomitant antiplatelet, NSAIDs, or paracetamol, n (%) 38 (36.2) 834 (20.7) 0.0001 
Concomitant CYP3A4 or P-gp inhibitors, n (%)# 31 (29.5) 824 (20.5) 0.0241 
Concomitant paracetamol, n (%) 9 (8.6) 141 (3.5) 0.0062 
Active cancer, n (%) 3 (2.9) 69 (1.7) 0.3778 
Prior bleeding, n (%) 1 (1.0) 30 (0.7) 0.8088 
Ulcerative gastrointestinal disease, n (%) 0 (0) 18 (0.4) 0.4921 
Uncontrolled hypertension, n (%) 7 (6.7) 142 (3.5) 0.0890 
Prior stroke, n (%) 21 (20.0) 587 (14.6) 0.1229 
Prior MI, n (%) 15 (14.3) 425 (10.6) 0.2229 
Heart failure at baseline, n (%) 40 (38.1) 811 (20.2) <0.0001 
Platelet count <80 000, n (%) 2 (2.6) 21 (0.8) 0.1051 
Diabetes mellitus, n (%) 28 (26.7) 828 (20.6) 0.1293 
Vascular disease, n (%) 50 (47.6) 1047 (26.0) <0.0001 
Alcohol consumption, n (%)   0.0299 
Abstinent or mild 95 (90.5%) 3629 (90.2)  
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 Medium 7 (6.7) 365 (9.1%)  
Heavy 3 (2.9) 28 (0.7)  
Anemia/reduced hemoglobin, n (%) 6 (5.7) 156 (3.9) 0.3390 
Known coagulopathy, n (%) 1 (1.0) 8 (0.2) 0.1023 
Bridging therapy during interruptions, n (%) 11 (10.5) 69 (1.7) <0.0001 
*Defined as ‘abnormal liver function’ by the study investigator. 
#Strong, moderate and weak inhibitors were included. 
ASA indicates acetylsalicylic acid; BMI, body mass index; CrCl, creatinine clearance; CYP3A4, cytochrome P450 3A4; MI, myocardial 
infarction; NSAID, nonsteroidal anti-inflammatory drug; P-gp, P-glycoprotein; SD, standard deviation. 
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 Table S7. Independent factors associated with major bleeding or death in the XANTUS population (N=6784).  
Risk factors HR 95% CI P-value 
Heart failure at baseline: Yes vs No 2.27 (1.64–3.16) <0.001 
Age (5-year increase) 1.21 (1.10–1.33) <0.001 
Concomitant antiplatelets, NSAIDs, or paracetamol 
use: Yes vs No 1.76 (1.26–2.47) <0.001 
Rivaroxaban dose (first documented): Overall   0.003 
Rivaroxaban dose (first documented): 20 mg vs 
15 mg 0.70 (0.49–0.99) 0.043 
Rivaroxaban dose (first documented): Other or 
missing vs 15 mg 3.35 (1.21–9.28) 0.020 
Vascular disease: Yes vs No 1.56 (1.13–2.16) 0.007 
Hepatic insufficiency: Yes vs No* 2.27 (1.21–4.27) 0.011 
Anemia or reduced hemoglobin use: Yes vs No 1.58 (0.92–2.70) 0.095 
Multivariable Cox proportional hazard model of time-dependent risk factors for treatment-emergent adjudicated major bleeding or treatment-
emergent adjudicated death. This analysis was performed as a sensitivity analysis for the factors predicting major bleeding. All factors with the 
exception of heavy alcohol use and uncontrolled hypertension were confirmed in the sensitivity analysis. Hepatic insufficiency, a common 
consequence of long-term heavy alcohol abuse, was associated with major bleeding or death.  
*Defined as ‘abnormal liver function’ by the study investigator. 
CI indicates confidence interval; HR, hazard ratio; NSAID, nonsteroidal anti-inflammatory drug.
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 Table S8. Alcohol equivalence.  
Alcohol 
consumption 
category 
Gram alcohol per 
day 
Country Glasses per day 
Beer  
(5% alcohol by 
volume) 
Wine  
(12% alcohol by 
volume) 
Spirits  
(40% alcohol by 
volume) 
Abstinent 0 All countries 0 0 0 
Mild <40 Germany, France, 
Italy, Japan 
<4 glasses at  
0.2 L/glass 
<2 glasses at  
0.2 L/glass 
<5 glasses at  
2 cL/glass 
United Kingdom <1.5 pints <3 glasses at  
125 mL/glass 
<4 measures at  
25 mL/glass 
Russia <2.5 glasses at  
0.33 L/glass 
– <2 glasses at  
50 mL/glass 
North America <2 cans at 12 fluid 
ounces/can 
<2 glasses at 5 fluid 
ounces/glass 
<2 glasses at 1.5 fluid 
ounces/glass 
Moderate 40–80 Germany, France, 
Italy, Japan 
4–8 glasses at  
0.2 L/glass 
2–4 glasses at  
0.2 L/glass 
5–10 glasses at  
2 cL/glass 
United Kingdom 1.5–3 pints 3–6 glasses at  
125 mL/glass 
4–8 measures at  
25 mL/glass 
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 Russia 2.5–5 glasses at  
0.33 L/glass 
– 2–4 glasses at  
50 mL/glass 
North America 2–4 cans at 12 fluid 
ounces/can 
2–5 glasses at 5 fluid 
ounces/glass 
2–4 glasses at 
1.5 fluid ounces/glass 
Heavy >80 Germany, France, 
Italy, Japan 
>8 glasses at  
0.2 L/glass 
>4 glasses at  
0.2 L/glass 
>10 glasses at  
2 cL/glass 
United Kingdom >3 pints >6 glasses at  
125 mL/glass 
>8 measures at  
25 mL/glass 
Russia >5 glasses at  
0.33 L/glass 
– >4 glasses at  
50 mL/glass 
North America >4 cans at 12 fluid 
ounces/can 
>5 glasses at 5 fluid 
ounces/glass 
>4 glasses at 1.5 fluid 
ounces/glass 
The categories of alcohol consumption (abstinent, mild, moderate, and heavy) were defined by the total daily alcohol content (in grams) 
consumed by the individual. The categories were created so that subgroup analyses could be performed.  
The definitions used are provided in the Table S5. For example: if an individual consumed beer at <800 mL/day (<40 g alcohol/day), he/she 
was classified as a mild alcohol consumer. However, if the individual consumed 500 mL/day of beer and 250 mL of wine, he/she was classified 
as a moderate alcohol consumer (25 g alcohol/day of beer + 30 g alcohol/day of wine = 55 g alcohol/day). 
If the country where the trial was being conducted is not listed in the table (eg, Sweden), the closest country could be used. For example, 
investigators in Sweden could use the ‘Germany, France, Italy, Japan’ category. 
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Table S9. Antithrombotic treatment as risk factors for major bleeding. 
Risk factors HR* 95% CI P-value 
Concomitant antiplatelet, NSAID or paracetamol 1.97 1.36–2.86 <0.001 
Concomitant antiplatelet 1.69 1.13–2.55 0.012 
Concomitant NSAID or paracetamol 2.19 1.23–3.88 0.007 
Concomitant paracetamol 2.64 1.34–5.19 0.005 
Concomitant antiplatelet or NSAID 1.77 1.20–2.61 0.004 
Concomitant NSAID 1.73 0.76–3.92 0.191 
*Shown for the comparison of concomitant antithrombotic therapy yes vs no in separate 
univariate Cox proportional hazard models. 
CI indicates confidence interval; HR, hazard ratio; NSAID, nonsteroidal anti-inflammatory 
drug.
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Table S10. Independent factors associated with major bleeding in the XANTUS 
population in a sensitivity analysis with imputation of missing CrCl values (n=5896).  
Risk factors HR 95% CI P-value 
Age (5-year increase) 1.27 1.14–1.41 <0.001 
Heart failure at baseline: Yes vs No 2.08 1.42–3.07 <0.001 
Vascular disease: Yes vs No 1.94 1.33–2.84 <0.001 
Concomitant antiplatelets, NSAIDs, or paracetamol 
use: Yes vs No 1.95 1.32–2.88 <0.001 
Alcohol consumption at baseline: Overall   0.090 
Alcohol consumption at baseline: Heavy vs 
Abstinent or mild 3.58 1.13–11.34 0.030 
Alcohol consumption at baseline: Medium vs 
Abstinent or mild 0.91 0.42–1.96 0.806 
A backwards selection was done using a P-value of 0.1 for variables to stay in the model. 
Candidate risk factors were used as for the primary analysis shown in Table S2. 
Patients with missing CrCl and CrCl ≥50 mL/min were grouped together because a 
comparison of baseline characteristics and event rates between patients with and without 
CrCl showed that those with missing data were generally healthier than those with available 
data, i.e. they have fewer co-morbidities (e.g. hypertension, prior stroke, heart failure and 
diabetes) and were less likely to have a stroke, bleeding event or die. 
CI indicates confidence interval; CrCl, creatinine clearance; HR, hazard ratio; INR, 
international normalized ratio; NSAID, nonsteroidal anti-inflammatory drug; P-gp, P-
glycoprotein.  
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Table S11. Major bleeding or death in the XANTUS population stratified by the number of modifiable bleeding risk factors. 
Number of modifiable 
risk factors 
Overall 
n (%) 
Patients with major 
bleeding events or death* 
n (%) 
Incidence proportion 
% (95% CI) 
Incidence rate 
Events per 100 years (95% CI) 
0 5150 (75.9) 148 (2.9) 2.87 (2.43–3.37) 3.15 (2.66–3.70) 
1 1577 (23.2) 81 (5.1) 5.14 (4.10–6.34) 6.00 (4.77–7.46) 
≥2 57 (0.8) 3 (5.3) 5.26 (1.10–14.62) 6.22 (1.28–18.18) 
Number of patients and major bleeding events or death from the XANTUS study were stratified according to the number of modifiable risk 
factors. 
*Treatment-emergent adjudicated. 
#Only one patient had three modifiable bleeding risk factors and did not experience a bleeding event. 
 
CI indicates confidence interval. 
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Table S12. Assessment of interactions between age and modifiable risk factors. 
Modifiable risk factor Age <75 years Age ≥75 years P-value (interaction)* 
Patients with 
major bleeding  
n/N (%) 
Incidence rate 
Events per 100 
patient-years 
(95% CI) 
Patients with 
major bleeding 
n/N (%) 
Incidence rate 
Events per 100 
patient-years 
(95% CI) 
Concomitant antiplatelet, NSAID 
or paracetamol 
Yes 
No 
 
 
17/757 (2.2) 
35/3218 (1.1) 
 
 
2.59 (1.51–4.15) 
1.18 (0.82–1.65) 
 
 
24/606 (4.0) 
52/2203 (2.4) 
 
 
4.75 (3.04–7.07) 
2.63 (1.97–3.45) 
0.997 
Alcohol consumption     0.746 
Abstinent or mild 42/3371 (1.2) 1.37 (0.99–1.85) 67/2562 (2.6) 2.97 (2.30–3.77)  
Medium 4/448 (0.9) 0.99 (0.27–2.54) 4/158 (2.5) 2.81 (0.77–7.20)  
Heavy 
 
2/42 (4.8) 
 
5.74 (0.70–20.75) 
 
1/12 (8.3) 
 
8.38 (0.21–46.68) 
 
 
Uncontrolled hypertension 
Yes 
No 
 
4/159 (2.5) 
48/3816 (1.3) 
 
2.92 (0.80–7.48) 
1.38 (1.02–1.83) 
 
4/116 (3.4) 
72 /2693(2.7) 
 
3.96 (1.08–10.14) 
3.03 (2.37–3.81) 
0.171 
*The interaction P-values were calculated using the model including age (continuous), heart failure, vascular disease, concomitant antiplatelet 
therapy, NSAID or paracetamol, alcohol consumption, uncontrolled hypertension and one interaction at a time. 
 
CI indicates confidence interval; NSAID, nonsteroidal anti-inflammatory drug.  
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Table S13. Major bleeding in the XANTUS population stratified by HAS-BLED and ORBIT bleeding risk scores and validation of the 
XANTUS bleeding score using Harrell’s C-index. 
Score category Overall  
n (%) 
Patients with 
major 
bleeding*  
n (%) 
Incidence 
proportion, % 
(95% CI) 
Incidence rate 
Events per 100 
years (95% CI) 
Harrell’s C of 
scores 
(individual 
score points) 
(95% CI) 
Harrell’s C of 
scores 
(categorizations) 
(95% CI) 
HAS-BLED score†     0.59 (0.55–0.64) 0.56 (0.52–0.61) 
Low (0) 318 (4.7) 1 (0.3) 0.31 (0.01–1.74) 0.36 (0.01–2.03)   
Medium (1–2) 4593 (67.7) 78 (1.7) 1.70 (1.34–2.11) 1.89 (1.49–2.35)   
High (≥3) 1854 (27.3) 48 (2.6) 2.59 (1.91–3.42) 2.88 (2.12–3.82)   
ORBIT score‡     0.62 (0.54–0.69) 0.59 (0.52–0.66) 
Low (0–2) 1192 (17.6) 27 (2.3) 2.27 (1.50–3.28) 2.61 (1.72–3.80)   
Medium (3) 270 (4.0) 13 (4.8) 4.81 (2.59–8.09) 5.89 (3.13–10.07)   
High (4–7) 240 (3.5) 11 (4.6) 4.58 (2.31–8.05) 5.54 (2.76–9.91)   
Number of patients and major bleeding events from the XANTUS study were stratified by HAS-BLED and ORBIT bleeding risk scores. The 
score for a patient is unknown if the information on one of the components of the score is missing. 
*Treatment emergent adjudicated. 
†Risk factors: Hypertension (uncontrolled), Abnormal renal and liver function (one point each), Stroke, Bleeding (history or predisposition 
(anemia)), Labile INRs, Elderly (>65 years), Drugs or alcohol (one point for antiplatelet agents, other anticoagulants or NSAIDs; one point for 
alcohol excess). 
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‡Risk factors: Older age (75 years or older), Reduced hemoglobin (<13 mg/dL in men and <12 mg/dL in women), hematocrit (<40% in men and 
<36% in women) or history of anemia, Bleeding history, Insufficient kidney function (eGFR <60 mg/dL/1.73 m2), Treatment with antiplatelets. 
CI indicates confidence interval; eGFR, estimated glomerular filtration rate; INR, international normalized ratio; NSAID, nonsteroidal anti-
inflammatory drug.
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Figure S1. Graphical assessment of the proportional hazards assumption of the risk factors. 
 
A, age; B, congestive heart failure; C, vascular disease; D, uncontrolled hypertension; E, alcohol usage; and F, NSAID or paracetamol usage. 
NSAID indicates nonsteroidal anti-inflammatory drug.  
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Figure S2. Assessment of linearity for age – smoothed plot of Martingale residuals. 
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Figure S3. Calibration plot assessing correlation between actual and predicted probabilities in the final multivariate model. 
 
 
d indicates number of patients with an event; N, number of patients. 
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